Reva Basho, MD
Medical Oncology · West Hollywood, CANPI 1508146721
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,941 of the $89,042 with a category attached, or 77.4%. 13 manufacturers reported payments, led by AstraZeneca at 52.2% of the total. 2025 is the largest year on record at $22,342, 7.8 times the $2,869 reported in 2019.
Across 88 payments — averaging $1011.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$47K
- Genentech USA, Inc.$11K
- Novartis$8K
- Pfizer$7K
- Lilly USA, LLC$6K
- Genentech, Inc.$5K
- plus $6K from 7 others
Across 70 payments — averaging $24,658 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.1M
- Seagen Inc.$366K
- Genentech, Inc.$157K
- Eli Lilly$36K
- Ichnos Glenmark Innovation Inc$30K
- Astrazeneca UK Limited$20K
- plus $25K from 3 others
What the payments were for
- Consulting fees$68,94177%
- Speaking & faculty fees$12,03014%
- Travel & lodging$4,9826%
- Food & beverage$3,0893%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $46,504 |
| Genentech USA, Inc. | 13 | $10,503 |
| Novartis | 14 | $8,349 |
| Pfizer | 7 | $6,901 |
| Lilly USA, LLC | 2 | $5,800 |
| Genentech, Inc. | 4 | $4,672 |
| Gilead | 3 | $3,313 |
| Seagen Inc. | 3 | $2,675 |
| Recordati_rare_diseases_inc. | 1 | $104 |
| Roche Products Limited | 2 | $103 |
| Puma Biotechnology, Inc. | 1 | $50 |
| Daiichi Sankyo Inc. | 1 | $48 |
| F. Hoffmann-la Roche AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,042 in reported general payments places this provider in the 80th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in West Hollywood
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.